These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34747507)
21. A Chinese case of concurrent anti-laminin γ1 pemphigoid and anti-laminin 332-type mucous membrane pemphigoid. Liu W; Sun X; Gao Y; Li H; Shi L; Cheng L; Zhou Z; Li X; Qian H J Dermatol; 2023 Feb; 50(2):e69-e71. PubMed ID: 35811504 [No Abstract] [Full Text] [Related]
31. [Rituximab use in mucous membrane pemphigoid]. Bertrand AS; Dereure O; Girard C; Bessis D; Guillot B Ann Dermatol Venereol; 2019 Oct; 146(10):659-661. PubMed ID: 31358309 [No Abstract] [Full Text] [Related]
32. A Review Comparing International Guidelines for the Management of Bullous Pemphigoid, Pemphigoid Gestationis, Mucous Membrane Pemphigoid, and Epidermolysis Bullosa Acquisita. Patel PM; Jones VA; Murray TN; Amber KT Am J Clin Dermatol; 2020 Aug; 21(4):557-565. PubMed ID: 32180161 [TBL] [Abstract][Full Text] [Related]
33. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoadsorption and rituximab. Hügel R; Lang A; Lhotta K; Elsässer W; Gächter J; Messmer EM; Schmidt E J Dtsch Dermatol Ges; 2018 Jul; 16(7):897-900. PubMed ID: 29927519 [No Abstract] [Full Text] [Related]
34. Immune-mediated subepithelial blistering diseases of mucous membranes. Pure ocular cicatricial pemphigoid is a unique clinical and immunopathological entity distinct from bullous pemphigoid and other subsets identified by antigenic specificity of autoantibodies. Chan LS; Yancey KB; Hammerberg C; Soong HK; Regezi JA; Johnson K; Cooper KD Arch Dermatol; 1993 Apr; 129(4):448-55. PubMed ID: 7682049 [TBL] [Abstract][Full Text] [Related]
35. World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus. Mays JW; Carey BP; Posey R; Gueiros LA; France K; Setterfield J; Woo SB; Sollecito TP; Culton D; Payne AS; Greenberg MS; De Rossi S Oral Dis; 2019 Jun; 25 Suppl 1(Suppl 1):111-121. PubMed ID: 31140696 [TBL] [Abstract][Full Text] [Related]
36. [Bullous Pemphigoid Successfully Treated with Rituximab]. Silva N; Costa A; Salvador F; Serradeiro E Acta Med Port; 2017 Mar; 30(3):243-246. PubMed ID: 28550834 [TBL] [Abstract][Full Text] [Related]
37. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients. Alexandre M; Bohelay G; Gille T; Le Roux-Villet C; Soued I; Morin F; Caux F; Grootenboer-Mignot S; Prost-Squarcioni C Front Immunol; 2022; 13():874108. PubMed ID: 35514989 [TBL] [Abstract][Full Text] [Related]
38. Oral manifestations of benign mucous membrane pemphigus (mucous membrane pemphigoid); review of the literature and report of fifteen cases. SHKLAR G; McCARTHY PL Oral Surg Oral Med Oral Pathol; 1959 Aug; 12(8):950-66. PubMed ID: 13674694 [No Abstract] [Full Text] [Related]
39. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). Maley A; Warren M; Haberman I; Swerlick R; Kharod-Dholakia B; Feldman R J Am Acad Dermatol; 2016 May; 74(5):835-40. PubMed ID: 26936298 [TBL] [Abstract][Full Text] [Related]
40. Frequency of IgA antibodies in pemphigus, bullous pemphigoid and mucous membrane pemphigoid. Cozzani E; Drosera M; Parodi A; Carrozzo M; Gandolfo S; Rebora A Acta Derm Venereol; 2004; 84(5):381-4. PubMed ID: 15370705 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]